| Expression pattern: |
UP |
| Associated gene: |
ITGA11, AGO2, MRP1, MDR1, Bcl-2, Bax |
| Associated microRNA: |
miR-515-5p |
| Biological function: |
CircPDSS1 promotes DDP resistance, cell proliferation, migration and invasion, and inhibits apoptosis in DDP-resistant gastric cancer cells; circPDSS1 depletion improves cisplatin sensitivity in vitro and in vivo. |
| Molecular mechanism: |
CircPDSS1 acts as a competing endogenous RNA by binding miR-515-5p, thereby positively regulating ITGA11 expression and conferring DDP resistance. |
| Biological pathway or process: |
chemoresistance (promotes); drug resistance (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Actinomycin D / DRB Stability Assay; RNase R Treatment; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; MTT; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis |
| Clinical significance: |
Interfering with the circPDSS1/miR-515-5p/ITGA11 pathway may be a potential target for the treatment of DDP-resistant gastric cancer. |
| Description: |
circPDSS1 is up-regulated in cisplatin-resistant gastric cancer tissues and cells. It promotes DDP resistance and malignant phenotypes by sponging miR-515-5p to increase ITGA11 expression, while circPDSS1 knockdown enhances DDP sensitivity in vitro and in a xenograft model. |
| Confidence score: |
0.8443 |